Using mass media and the internet as tools to diagnose hepatitis Cinfections in the general population

American Journal of Preventive Medicine

Volumn 40, Issue 3, 2011, Pages 345-352

  Zuure, Freke R ^a   Davidovich, Udi ^a   Coutinho, Roel A ^b,d   Kok, Gerjo ^e   Hoebe, Christian J P A ^f   Van Den Hoek, Anneke ^a,b   Jansen, Peter L M ^c   Van Leeuwen Gilbert, Paula ^g   Verheuvel, Nicole C ^a   Weegink, Christine J ^c   Prins, Maria ^a,b  

^a DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^b CINIMA   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f South Limburg Public Health Service   (Netherlands)

^g National Hepatitis Centre   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY;

ADULT; ANTIBODY DETECTION; ARTICLE; BLOOD ANALYSIS; BLOOD TRANSFUSION; FEASIBILITY STUDY; FEMALE; HEPATITIS C; HUMAN; INTERNET; MAJOR CLINICAL STUDY; MALE; MASS MEDIUM; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; VALIDATION PROCESS;

ADULT; FEASIBILITY STUDIES; FEMALE; HEMATOLOGIC TESTS; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; INTERNET; MALE; MASS MEDIA; MASS SCREENING; MIDDLE AGED; NETHERLANDS; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS;

EID: 79951760829     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amepre.2010.11.019     Document Type: Article

References (39)

1. Perz JF, Farrington LA, Pecoraro C, Hutin YJ, Armstrong GL. Estimated global prevalence of hepatitis C virus infection. 42nd Annual Meeting of the Infectious Diseases Society of America; 2004 Sep 30-Oct 3, Boston MA. Abstract available at http://www.idsociety.org/ WorkArea//DownloadAsset.aspx?id=2034, paper 957.
2. McHutchison JG. Understanding hepatitis C. Am J Manag Care 2004;10:S21-9.
3. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006;13:34-41.
4. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36(5S 1):S35-46.
5. Sypsa V, Touloumi G, Papatheodoridis GV, et al. Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. J Viral Hepat 2005;12:543-50. (Pubitemid 41224261)
6. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and HIV infections in the U.S. J Viral Hepat 2007;14:107-15. (Pubitemid 46146705)
7. NIH. NIH Consensus Development Conference Statement: management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002;36:S3-20.
8. Vrolijk JM, de Knegt RJ, Veldt BJ, Orlent H, Schalm SW. The treatment of hepatitis C: history, presence and future. Neth J Med 2004;62:76-82. (Pubitemid 39089464)
9. Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003;52:425-32. (Pubitemid 36250066)
10. Grishchenko M, Grieve RD, Sweeting MJ, et al. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. Int J Technol Assess Health Care 2009;25:171-80.
11. Wong JB. Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics 2006;24:661-72. (Pubitemid 43998819)
12. Takkenberg B, de Bruijne J, Weegink C, Jansen P, Reesink H. Novel therapies in hepatitis B and C. Curr Gastroenterol Rep 2008;10:81-90.
13. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362:1292-303.
14. Expert Consensus Conference. The screening for hepatitis C virus infection in adults in Italy, May 5-6, 2005. Dig Liver Dis 2006;38:445-51.
15. Van den Hoek JA, van Haastrecht HJ, Goudsmit J, de Wolf F, Coutinho RA. Prevalence, incidence, and risk factors of hepatitisCvirus infection among drug users in Amsterdam. J Infect Dis 1990;162:823-6. (Pubitemid 20336518)
16. Lucidarme D, Decoster A, Fremaux D, et al. Routine practice HCV infection screening with saliva samples: multicentric study in an intravenous drug user population. Gastroenterol Clin Biol 2007;31:480-4. (Pubitemid 46877546)
17. Makris M, Baglin T, Dusheiko G, et al. Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia. Haemophilia 2001;7:339-45. (Pubitemid 32677650)
18. Plug I, van der Bom JG, Peters M, et al. Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood 2004;104:3494-500.
19. Williams JL, Cagle HH, Christensen CJ, Fox-Leyva LK, McMahon BJ. Results of a hepatitis C general transfusion lookback program for patients who received blood products before July 1992. Transfusion 2005;45:1020-6.
20. Goldman M, Patterson L, Long A. Recent Canadian experience with targeted hepatitis C virus lookback. Transfusion 2006;46:690-4.
21. Bowker SL, Smith LJ, Rosychuk RJ, Preiksaitis JK. A review of general hepatitis C virus lookbacks in Canada. Vox Sang 2004;86:21-7. (Pubitemid 38200452)
22. Menozzi D, Udulutch T, Llosa AE, Galel SA.HCVlookback in the U.S.: effectiveness of an extended lookback program. Transfusion 2000;40:1393-8.
23. Lapane KL, Jakiche AF, Sugano D, Weng CS, Carey WD. Hepatitis C infection risk analysis: who should be screened? Comparison of multiple screening strategies based on the National Hepatitis Surveillance Program. Am J Gastroenterol 1998;93:591-6. (Pubitemid 29081008)
24. Mallette C, Flynn MA, Promrat K. Outcome of screening for hepatitis C virus infection based on risk factors. Am J Gastroenterol 2008;103:131-7.
25. McGinn T, O'Connor-Moore N, Alfandre D, Gardenier D, Wisnivesky J. Validation of a hepatitisCscreening tool in primary care. Arch Intern Med 2008;168:2009-13.
26. Stein K, Dalziel K, Walker A, et al. Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice. Health Technol Assess 2002;6:1-122.
27. Nakamura J, Terajima K, Aoyagi Y, Akazawa K. Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups. Tohoku J Exp Med 2008;215:33-42. (Pubitemid 351791266)
28. Houston TK, Cooper LA, Vu HT, Kahn J, Toser J, Ford DE. Screening the public for depression through the Internet. Psychiatr Serv. 2001;52:362-7. (Pubitemid 32259672)
29. Koekenbier RH, Davidovich U, van Leent EJ, Thiesbrummel HF, Fennema HS. Online-mediated syphilis testing: feasibility, efficacy, and usage. Sex Transm Dis 2008;35:764-9.
30. Health Council of the Netherlands: Committee on Hepatitis C. Detection and treatment of people with hepatitis C. Publication no. 1997/19. Rijswijk: Health Council of the Netherlands, 1997.
31. Slavenburg S, Verduyn-Lunel FM, Hermsen JT, Melchers WJ, te Morsche RH, Drenth JP. Prevalence of hepatitis C in the general population in the Netherlands. Neth J Med 2008;66:13-7. (Pubitemid 351188284)
32. Zuure FR, Davidovich U, Kok G, et al. Evaluation of a risk assessment questionnaire to assist hepatitis C screening in the general population. Euro Surveill 2010;15(15):19539.
33. Reips UD. Standards for Internet-based experimenting. Exp Psychol 2002;49:243-56.
34. WHO. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997;72:341-4.
35. Jepson R, Clegg A, Forbes C, Lewis R, Sowden A, Kleijnen J. The determinants of screening uptake and interventions for increasing uptake: a systematic review. Health Technol Assess 2000;4:i-133.
36. Giesbers H, Frenken F. Cervix uitstrijkjes en Mammografie 2004-2007. In: Volksgezondheid Toekomst Verkenning, Nationale Atlas Volksgezondheid. 23-6-2009. Bilthoven, Netherlands: RIVM.
37. Scheinmann R, Hagan H, Lelutiu-Weinberger C, et al. Non-injection drug use and hepatitis C virus: a systematic review. Drug Alcohol Depend 2007;89:1-12. (Pubitemid 46602869)
38. DeFrank JT, Rimer BK, Gierisch JM, Bowling JM, Farrell D, Skinner CS. Impact of mailed and automated telephone reminders on receipt of repeat mammograms: a randomized controlled trial. Am J Prev Med 2009;36:459-67.
39. Sequist TD, Zaslavsky AM, Marshall R, Fletcher RH, Ayanian JZ. Patient and physician reminders to promote colorectal cancer screening: a randomized controlled trial. Arch Intern Med 2009;169:364-71.